Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma

被引：56

作者：

Waldmann, T. A. ^{[1
]}

机构：

[1] NCI, Metab Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

来源：

ONCOGENE | 2007年 / 26卷 / 25期

关键词：

IL-2; receptor; adult T-cell leukemia; anti-Tac; monoclonal antibody;

D O I：

10.1038/sj.onc.1210368

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Daclizumab (Zenapax) identifies the alpha subunit of the interleukin-2 (IL-2) receptor and blocks the interaction of this cytokine with its growth factor receptor. The scientific basis for the choice of the IL-2 receptor alpha subunit as a target for monoclonal antibody-mediated therapy of leukemia/lymphoma is that very few normal cells express IL-2R alpha, whereas the abnormal T cells in patients with an array of lymphoid malignancies express this receptor. In 1997, daclizumab was approved by the FDA for use in the prevention of renal allograft rejection. In addition, anti-Tac provided effective therapy for select patients with T-cell malignancies and an array of inflammatory autoimmune disorders. Finally, therapy with this antibody armed with Y-90 has led to clinical responses in the majority of patients with adult T-cell leukemia. These insights concerning the IL-2/IL-2 receptor system facilitated the development of effective daclizumab antibody therapy for select patients with leukemia/lymphoma.

引用

页码：3699 / 3703

页数：5

共 42 条

[11]

LEONARD WJ, 1985, J BIOL CHEM, V260, P1872

[12] MOLECULAR-CLONING AND EXPRESSION OF CDNAS FOR THE HUMAN INTERLEUKIN-2 RECEPTOR [J].

LEONARD, WJ ;

DEPPER, JM ;

CRABTREE, GR ;

RUDIKOFF, S ;

PUMPHREY, J ;

ROBB, RJ ;

KRONKE, M ;

SVETLIK, PB ;

PEFFER, NJ ;

WALDMANN, TA ;

GREENE, WC .

NATURE, 1984, 311 (5987) :626-631

[13] A MONOCLONAL-ANTIBODY THAT APPEARS TO RECOGNIZE THE RECEPTOR FOR HUMAN T-CELL GROWTH-FACTOR - PARTIAL CHARACTERIZATION OF THE RECEPTOR [J].

LEONARD, WJ ;

DEPPER, JM ;

UCHIYAMA, T ;

SMITH, KA ;

WALDMANN, TA ;

GREENE, WC .

NATURE, 1982, 300 (5889) :267-269

[14] Cutting edge:: In vivo blockade of human IL-2 receptor induces expansion of CD56bright regulatory NK cells in patients with active uveitis [J].

Li, ZQ ;

Lim, WK ;

Mahesh, SP ;

Liu, BY ;

Nussenblatt, RB .

JOURNAL OF IMMUNOLOGY, 2005, 174 (09) :5187-5191

[15] Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia [J].

Maciejewski, JP ;

Sloand, EM ;

Nunez, O ;

Boss, C ;

Young, NS .

BLOOD, 2003, 102 (10) :3584-3586

[16] Advances in interleukin 2 receptor targeted treatment [J].

Morris, JC ;

Waldmann, TA .

ANNALS OF THE RHEUMATIC DISEASES, 2000, 59 :109-114

[17] Reduction of acute renal allograft rejection by daclizumab [J].

Nashan, B ;

Light, S ;

Hardie, IR ;

Lin, A ;

Johnson, JR .

TRANSPLANTATION, 1999, 67 (01) :110-115

[18] Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial [J].

Nussenblatt, RB ;

Fortin, E ;

Schiffman, R ;

Rizzo, L ;

Smith, J ;

Van Veldhisen, P ;

Sran, P ;

Yaffe, A ;

Goldman, CK ;

Waldmann, TA ;

Whitcup, SM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (13) :7462-7466

[19]

OMAHONEY D, 2006, J NUCL MED, V47, pP98

[20]

Phillips KE, 2000, CANCER RES, V60, P6977

← 1 2 3 4 5 →